Project Grant R41HL176288
Award Date
9/23/24
Completion Date
9/22/25
Dollars Obligated
$791K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Circulatech LLC (YP7WJGXFNGP5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Miramar, FL 33029, USA
Similar Awards
This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $298,368 Project Grant to Link Medical LLC in Chelsea, Michigan. The funding supports the development of a novel catheter-based device for treating mitral valve regurgitation, a prevalent cardiovascular condition expected to impact over 4 million Americans by 2030. The project aims to optimize the device design and procedural details through bench testing, followed...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop and test a drug-eluting chest tube to locally manage the pain associated with its use in cardiothoracic surgeries. The $275,752 award supports two key objectives: 1) completing GMP/GLP studies on the drug release kinetics, stability, and manufacturing of the drug-releasing chest tube; and 2) evaluating the mechanical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $229,971 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of North Carolina at Chapel Hill (UNC-CH) to develop and test novel hydrogel patches that can prevent air leaks after lung surgery. The goal is to eliminate the need for chest tubes following lung resection procedures, which would reduce complications, costs, and improve patient quality of life. The project involves optimizing the hydrogel...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the continued clinical development of a novel pleural and tracheal sealant. The $381,000 award to the University of Vermont will fund research to: 1) define optimal manufacturing, sterilization, and storage conditions for the sealant patch; 2) further evaluate the long-term safety and efficacy of the sealant in animal models...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,989,548 to Cerulean Scientific Inc. to develop a slippery, omniphobic coating for peripheral vascular grafts. The goal is to prevent thrombosis, biofilm formation, and other complications that frequently lead to graft failure. Over the 2.75-year project period ending June 2027, the funding will support in vitro characterization of the coating's durability and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,027,737 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to 3DT Holdings, LLC, a minority-owned biomedical engineering company. The objective of this "fast-track" proposal is to develop and validate a machine learning (ML)-based software tool for optimizing MitraClip placement procedures and predicting key outcomes like mitral regurgitation, left atrial pressure, and cardiac tissue...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $691,326 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Northwestern University to develop a "4D Right-Heart Virtual Catheter (4D VCATH)". This novel technology combines advanced mathematical modeling and 4D flow MRI to provide a comprehensive, non-invasive hemodynamic analysis of the right heart chambers. The project aims to enable streamlined diagnosis, classification, and prognosis...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,751 to Third Coast Dynamics, Inc. to develop an artificial intelligence-based platform called "TCDFLOW" that can derive 4D hemodynamic data from routine clinical anatomic images. This will address limitations of current 4D flow MRI techniques, which require specialized equipment and expertise, by enabling the...
The National Heart, Lung, and Blood Institute (NHLBI), under the federal Cardiovascular Diseases Research program (CFDA 93.837), awarded a $306,643 project grant to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed to efficiently accommodate the low flow rates needed for pediatric and neonatal patients. The project aims to design, develop, and test a low-flow ECMO pump capable of operating at flow rates from 0.05 to 0.5 L/min, which is an order of...